サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：低酸素症治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1319136

低酸素症治療の世界市場-2023年～2030年

Global Hypoxia Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
低酸素症治療の世界市場-2023年～2030年
出版日: 2023年07月31日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の低酸素症治療市場は、2022年に7,760万米ドルに達し、2023-2030年の予測期間中にCAGR 7.2％で成長し、2030年には1億3,430万米ドルに達すると予測されています。低酸素状態の有病率の増加、技術の絶え間ない進歩、臨床試験の増加、消費者需要の増加、FDA認可の増加などの要因が低酸素症治療市場を押し上げる可能性が高いです。

低酸素状態は、病原微生物感染、がん、急性および慢性疾患、その他多くのストレス反応など、いくつかの生物学的プロセスに関連しています。低酸素誘導因子（HIF）は低酸素を感知して一連の下流遺伝子の発現を制御し、細胞代謝、細胞死、細胞増殖、解糖、免疫反応、微生物感染、転移を含む複数のプロセスに関与します。

市場力学

低酸素症治療における技術進歩の高まりが世界市場の成長を後押しする見込み

低酸素症治療市場は、さまざまな技術の進歩により大きな成長を遂げています。多くの主要企業が新製品や新サービスを発売することで、こうした進歩に大きな役割を果たしています。この新製品やサービスは、診断や医療機器の生産性や有効性を高めることができます。

例えば、2023年6月20日、Akebia Therapeutics, Inc.は、慢性維持透析を受けている成人における慢性腎臓病（CKD）に伴う症候性貧血の治療薬として、経口低酸素誘導因子プロリル水酸化酵素（HIF-PH）阻害剤であるVafseo（vadadustat）の販売承認をスイスの治療製品担当機関から取得したと発表しました。

VafseoのSwissmedicによる承認は、透析を受けている成人患者を対象としたCKDに起因する貧血治療のためのvadadustatの第3相臨床プログラムを含む、7,500人以上の患者を含む開発プログラムのデータに基づいています。このように、上記の要因から、予測期間中、市場は牽引役となることが期待されます。

低酸素状態に対するFDA承認の増加が世界の低酸素症治療市場を押し上げる見通し

喘息、COPD、肺炎などの低酸素状態に対するFDA承認の増加は、市場成長の主要な促進要因として作用します。また、多くの主要企業が新製品やサービスを発売することで、市場の進歩に大きな役割を果たしています。

例えば、2021年8月13日、Merck & Co.は、経口低酸素誘導因子-2α（HIF-2α）阻害剤であるWELIREGが、関連する腎細胞がん、中枢神経系血管芽腫または膵神経内分泌腫瘍に対する治療を必要とするVon Hippel-Lindau（VHL）疾患の成人患者の治療薬としてFDAの承認を取得したと発表しました。

さらに、米国食品医薬品局（FDA）は2022年3月15日、Symbicort Inhalation Aerosolの最初のジェネリック医薬品を、6歳以上の患者の喘息と、慢性気管支炎を含む慢性閉塞性肺疾患（COPD）患者の気流閉塞の維持治療および増悪の抑制という2つの一般的な肺疾患の治療薬として承認しました。この複合ジェネリック医薬品は、急性喘息発作の治療には使用されないです。したがって、上記の要因から、予測期間中、市場は牽引役となることが期待されます。

COPDなどの低酸素状態に関連する認識不足が世界の低酸素症治療市場成長の妨げになる見通し

Dove Pressによると、サウジアラビアのAseer地域におけるCOPDの有病率にアクセスするために疫学調査が実施されました。この地域の人々の間ではCOPDの認知度は低かっています。禁煙がCOPDの予防に重要な役割を果たすことを正しく知っていたのは34.0％のみでした。本研究では、一般住民のCOPDとその危険因子に対する認識を高めることが急務です。このテーマはカリキュラムで強化されるべきであり、公共キャンペーンやセミナーで議論されるべきです。さらに、国民の肺の健康を促進するための適切な予防・治療戦略を実施するために、政策立案者の助けとなる全国的な研究が必要です。

COVID-19の影響分析

COVID-19の流行は低酸素症治療薬市場に大きな影響を与えました。パンデミックの最盛期には、多くの医療システムが圧倒され、緊急性のない医療処置やスクリーニングは延期または中止されました。このため、低酸素状態の診断や患者の治療開始が遅れることになっています。その結果、低酸素症患者の一部は診断が遅れ、治療成績に影響を及ぼす可能性があっています。

臨床試験は、低酸素症治療市場における新たな治療法の開拓と治療成績の向上に不可欠です。しかし、パンデミックにより臨床試験の実施が中断され、多くの施設が患者の安全性を優先するために一時的に登録を中止したり、プロトコールを変更したりしました。このため、臨床試験の完了が遅れ、新しい治療法の入手が遅れることになっています。

さらに、研究開発の焦点はパンデミック中にシフトし、COVID-19に対するワクチンや治療法の開発に重点が置かれました。このような資源と関心の転用は、低酸素症関連の研究開発活動の進展に一時的に影響を与えた可能性があります。

また、COVID-19感染のリスクを最小限に抑えるため、医療提供者は、対面診療の削減、遠隔診療の増加、治療スケジュールの変更など、治療提供における変更を実施しました。こうした変化は、患者の全体的な経験や低酸素症治療市場の経営に影響を与えています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争は、医療や喘息やCOPDなどの低酸素症の管理を含め、両国の生活のさまざまな側面に重大な影響を及ぼしています。紛争は、影響を受けた地域の医療インフラの破壊と崩壊につながっています。病院や診療所などの医療施設が被害を受けたり、アクセスできなくなったりすることで、低酸素症の患者が適切な診断、治療、フォローアップを受けることが課題となります。

紛争の結果、医療機器、医薬品、専門的な医療専門家などの医療資源の利用が制限される可能性があります。このような不足は、低酸素症患者の診断の遅れ、不十分な治療選択肢、最適とはいえない疾病管理につながる可能性があります。

紛争は人口の移動をもたらし、人々は家を離れ、安全な地域に避難することを余儀なくされています。このような人口移動は、患者のケアの継続性を乱す可能性があり、患者は通常の医療提供者や治療施設へのアクセスが困難となり、慢性疼痛障害の治療が中断される可能性があります。

さらに、紛争とその余波は、被災地における低酸素症に関するデータ収集や調査努力を妨げる可能性があります。このことは、最新の疫学データの入手に影響を与え、臨床試験の妨げとなり、紛争被災地における低酸素症の治療成績の理解を制限する可能性があります。したがって、上記の要因を考慮すると、低酸素症治療市場はロシアとウクライナの紛争から中程度の影響を受けています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 低酸素状態に対するFDA承認の増加
      • 低酸素状態の臨床試験の増加
    • 抑制要因
      • 低酸素状態に関する認識不足
    • 機会
      • 低酸素症治療の新興市場
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 タイプ別

  • 低酸素性
  • 貧血性
  • 組織毒性
  • 停滞性

第9章 疾患タイプ別

  • 喘息
  • 慢性閉塞性肺疾患（COPD）
  • 肺炎
  • その他

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東およびアフリカ

第12章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第13章 企業プロファイル

  • CASI Pharmaceuticals Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Aileron Therapeutics, Inc., LLC.
  • Lupin Pharmaceuticals, Inc.
  • PharmaShots
  • Hancock Medical Inc.
  • Hamilton Company
  • Spotlight Labs
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co.

第14章 付録

目次
Product Code: PH6548

Market Overview

Global Hypoxia Treatment Market reached US$ 77.6 million in 2022 and is expected to reach US$ 134.3 million by 2030 growing with a CAGR of 7.2% during the forecast period 2023-2030. Factors such as the increasing prevalence of hypoxia conditions, continuous advancements in technology, rising clinical trials, increasing consumer demand, and growing FDA approvals are likely to boost the hypoxia treatment market.

Hypoxia is linked to several biological processes which include pathogenic microbe infection, cancers, acute and chronic diseases, and many other stress responses. Hypoxia-inducible factors (HIFs) sense hypoxia to regulate the expressions of a series of downstream genes expression, which participate in multiple processes including cell metabolism, cell death, cell proliferation, glycolysis, immune response, microbe infection, and metastasis.

Market Dynamics

Rising Technological Advancements in Hypoxia Treatment are Expected to Boost the Global Market Growth

The hypoxia treatment market has witnessed significant growth due to various technological advancements. Many key players play a major role in these advancements by launching new products and services. This new product or service can rise the productivity and efficacy of the diagnostic or medical device.

For instance, on June 20, 2023, Akebia Therapeutics, Inc. announced that the Swiss agency for therapeutic products granted marketing authorization for Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

The Swissmedic approval of Vafseo is based on data from a development program that included over 7,500 patients, including the global Phase 3 clinical program of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Rising FDA Approvals for Hypoxia Conditions are Expected to Boost the Global Hypoxia Treatment Market

The increasing FDA approvals for hypoxia conditions such as asthma, COPD, and pneumonia act as a major driver for the market growth. Also, many key players play a major role in the advancements of the market by launching new products and services.

For instance, on Aug 13, 2021, Merck & Co. announced that WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor received FDA approval for the treatment of adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.

Additionally, on March 15, 2022, the U.S. Food and Drug Administration (FDA) approved the first generic of Symbicort Inhalation Aerosol for the treatment of two common pulmonary health conditions that is asthma in patients six years of age and older and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis. This complex generic drug-device combination product, are not used to treat acute asthma attacks. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Lack of Awareness Associated with Hypoxia Conditions such as COPD is Expected to Hamper Global Hypoxia Treatment Market Growth

According to Dove Press, epidemiological studies were conducted to access the prevalence of COPD in the Aseer region of Saudi Arabia. The awareness regarding the COPD condition was low among the people of the region. Only 34.0% correctly knew that quitting smoking has an important role in preventing COPD. This study needs an urgent need of improving awareness of COPD and its risk factors in the general population. This subject should be strengthened in the curriculum and discussed in public campaigns and seminars. Furthermore, nationwide study is required to help the policymakers for implementing suitable preventive and curative strategies to promote the pulmonary health of the population.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the hypoxia treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in the diagnosis of hypoxia conditions and initiation of treatment for patients. As a result, some hypoxia disease cases were diagnosed at later stages, potentially affecting treatment outcomes.

Clinical trials are vital for developing new treatments and improving outcomes in the hypoxia treatment market. However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of hypoxia related research and development activities.

Also, to minimize the risk of COVID-19 transmission, healthcare providers implemented changes in treatment delivery, such as reducing in-person clinic visits, increasing telemedicine consultations, and modifying treatment schedules. These changes have impacted the overall patient experience and the management of the hypoxia treatment market.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of hypoxic diseases such as asthma and COPD. The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and clinics, may be damaged or inaccessible, making it challenging for patients with hypoxic diseases to receive proper diagnosis, treatment, and follow-up care.

The conflict can result in limited availability of medical resources, including medical devices, medications, and specialized healthcare professionals. This scarcity may lead to delays in diagnosis, inadequate treatment options, and suboptimal disease management for hypoxic disorders patients.

The conflict has resulted in population displacement, with people forced to leave their homes and seek refuge in safer areas. This displacement can disrupt patients' continuity of care, as they may have difficulty accessing their regular healthcare providers and treatment facilities, potentially leading to interruptions in their chronic pain disorder treatment.

Furthermore, the conflict and its aftermath may hinder data collection and research efforts related to hypoxic diseases in the affected regions. This can impact the availability of up-to-date epidemiological data, hinder clinical trials, and limit the understanding of hypoxic treatment outcomes in conflict-affected areas. Therefore, considering the above factors, the hypoxic treatment market has been moderately affected by the conflict between Russia and Ukraine.

Segment Analysis

The global hypoxia treatment market is segmented based on type, disease type, end users, and region.

Owing to Rising Clinical Trials, the Hypoxic Hypoxia Segment Accounted for Approximately 48.6% of the Hypoxia Treatment Market Share

According to ClinicalTrials.gov, on April 25, 2023, Capital Medical University conducted a clinical trial on an exploratory study of intermittent hypoxia treatment in chronic cerebral hypoperfusion. This interventional study aims to investigate the safety and efficacy of intermittent hypoxia treatment in patients with chronic cerebral hypoperfusion. This study is an exploratory study combining intermittent hypoxia treatment with chronic cerebral hypoperfusion, aiming to preliminarily explore the safety and potential effectiveness of intermittent hypoxia treatment in the use of chronic cerebral hypoperfusion. The estimated study completion date is Oct 10, 2023.

Additionally, On Feb 1, 2023, GSK announced that Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) has received the US Food and Drug Administration (FDA), for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for four months. Jesduvroq is the first innovative medicine for anemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral and convenient option for patients in the US with anemia of CKD on dialysis. Thus, owing to the above factors, the CMOS segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing Research and Development Activities and Well-Established Healthcare Infrastructure

The North American region is anticipated to experience growth in the field of hypoxia treatments due to factors such as rising research and development efforts, a robust healthcare infrastructure, and supportive reimbursement systems. These factors contribute to increased accessibility for patients to access advanced therapies, facilitating the adoption of cutting-edge treatments. This trend is expected to drive the North American region's progress in hypoxia treatment throughout the forecast period.

For instance, on Aug 13, 2021, Merck & Co. announced that WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor received FDA approval for the treatment of adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.

WELIREG is the first HIF-2α inhibitor therapy approved in the U.S. As an inhibitor of HIF-2α, WELIREG reduces transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.

Competitive Landscape

The major global players in the market include: CASI Pharmaceuticals Inc., Aileron Therapeutics, Inc., Lupin Pharmaceuticals, Inc., PharmaShots, Hancock Medical Inc., Hamilton Company, Spotlight Labs, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., and Merck & Co among others.

Why Purchase the Report?

  • To visualize the global hypoxia treatment market segmentation based on the type, disease type, end users, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of hypoxia treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global hypoxia treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Disease Type
  • 3.3. Snippet by End Users
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising FDA Approvals for Hypoxia Conditions
      • 4.1.1.2. Increasing Clinical Trials for Hypoxia Conditions
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Awareness Associated with Hypoxia Conditions
    • 4.1.3. Opportunity
      • 4.1.3.1. Emerging market of Hypoxia treatment
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Hypoxic Hypoxia*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Hypemic Hypoxic
  • 8.4. Histotoxic Hypoxia
  • 8.5. Stagnant Hypoxia

9. By Disease Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.1.2. Market Attractiveness Index, By Disease Type
  • 9.2. Asthma*
  • 9.3. Chronic Obstructive Pulmonary Disease (COPD)
  • 9.4. Pneumonia
  • 9.5. Others

10. By End Users

    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.1.2. Market Attractiveness Index, By End Users
  • 10.2. Hospitals
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. U.K.
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. CASI Pharmaceuticals Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Aileron Therapeutics, Inc., LLC.
  • 13.3. Lupin Pharmaceuticals, Inc.
  • 13.4. PharmaShots
  • 13.5. Hancock Medical Inc.
  • 13.6. Hamilton Company
  • 13.7. Spotlight Labs
  • 13.8. GlaxoSmithKline plc
  • 13.9. Sun Pharmaceutical Industries Ltd.
  • 13.10. Merck & Co.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us